Regulators must move faster on innovative medicines

While the Therapeutic Goods Administration works quickly to review new medicines, the funding process post-review needs streamlining.

Related Keywords

Canada ,Indonesia ,United States ,Australia ,Philippines ,Australian ,American ,Christine Cockburn ,John Skerritt ,Drug Administration ,Therapeutic Goods Administration ,Professor John Skerritt ,Medicines Australia ,Rare Cancers Australia ,Pharmaceutical Benefits Scheme ,Cancers Australia ,